ZARONTIN SYRUP Rx
Generic Name and Formulations:
Ethosuximide 250mg/5mL; oral soln; raspberry flavor.
Indications for ZARONTIN SYRUP:
Initially: 500mg daily. Increase every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses.
<3yrs: not established. 3–6yrs: initially 250mg daily. >6yrs: initially 500mg daily. Increase both every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses. Usual maintenance: 20mg/kg/day in divided doses.
Impaired hepatic or renal function. May precipitate tonic-clonic seizures. Discontinue at 1st sign of rash; consider alternative therapy if signs/symptoms of Stevens-Johnson syndrome occurs. Evaluate immediately if signs/symptoms of DRESS/multi-organ hypersensitivity develop; discontinue if no alternative etiology. Monitor for depression, suicidal ideation, unusual changes in mood/behavior. Monitor CBCs, kidney and liver function periodically. Change dose gradually. Pregnancy. Nursing mothers: not recommended.
Monitor phenytoin, phenobarbital, valproic acid, other AEDs.
Blood dyscrasias, drowsiness, ataxia, dizziness, headache, GI upset, CNS and psychiatric effects, rash (may be fatal), SLE, DRESS, gingival hyperplasia.
Caps, syrup (YES)
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Whole Genome Sequencing Use in Predicting TB Resistance
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Success With DAA for Hepatitis C Prior to Stem Cell Transplant
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- Dolutegravir Plus Lamivudine Promising for HIV Maintenance Therapy
- Trial Results Affected by Heterogeneous CAP Inclusion Criteria
- Screening Blood Donations Mitigates Transfusion-Transmitted Babesiosis Risk